United States Patent 10,239,927: What the Claims Actually Cover and Where the Landscape Breaks
US Patent 10,239,927 centers on a treatment method for arthritis and/or articular cartilage damage by administering a polypeptide comprising SEQ ID NO: 28, plus optional combinations with standard cartilage-support regimens (hyaluronic acid, MSC chondrogenic co-factors, and selected anti-inflammatories or growth factors). The same core polypeptide also drives a MSC-to-chondrocyte differentiation method in vivo or in connection with arthritis/cartilage damage.
From a patent-analytic standpoint, the claims are broad at the “polypeptide + therapeutic context” level, but they also contain several built-in narrowing hooks: SEQ ID NO: 28, joint-specific delivery, defined cartilage markers (type II collagen or aggrecan and type X collagen), and linkage to specific procedural frameworks (ACI/MACI, cartilage replacement, bone marrow stimulation).
What Are the Independent Claims and the Claim Spine?
Claim 1: Method of treating arthritis or articular cartilage damage
Claim 1 is the central independent claim:
- Method: treat or ameliorate arthritis or articular cartilage damage
- Administration: to a joint of a subject
- Agent: “a therapeutically effective amount of a polypeptide comprising SEQ ID NO: 28”
Claim 1 is then refined by dependent claims covering:
- arthritis types (osteoarthritis, trauma arthritis, autoimmune arthritis)
- combination therapies (chondrogenic factors; hyaluronic acid/derivatives; additional agents including selected drug classes and bioactives)
- procedural contexts (surgery; bone marrow stimulation; cartilage replacement; ACI; MACI)
- formulation context (matrix or biocompatible scaffold)
- biological response readouts (hyaline cartilage markers; fibrotic cartilage markers)
Claim 15: MSC differentiation into chondrocytes
Claim 15 is the second independent claim:
- Method: induce differentiation of mesenchymal stem cells into chondrocytes
- Contact: mesenchymal stem cells with an effective amount of the polypeptide comprising SEQ ID NO: 28
Dependent claims (16-20) connect this to in vivo human settings, arthritis/cartilage damage, and the same add-on regimen universe (additional chondrogenic factors; hyaluronic acid/derivative; and the listed anti-inflammatory/growth factor or osteo-cartilage-related agents).
Claim spine: two process types, both anchored to the same constrained entity definition: a polypeptide comprising SEQ ID NO: 28.
How Broad or Narrow Are These Claims in Practice?
What the claims clearly cover (broad dimensions)
- Arthritis and articular cartilage damage: the claim does not limit by anatomical joint type beyond “a joint.”
- Therapeutically effective amount: no dosing range, no route, no schedule, and no delivery device is required in the claim text you provided.
- Polypeptide phrasing: “polypeptide comprising SEQ ID NO: 28” can be read to cover constructs that include SEQ ID NO: 28 as part of a larger molecule (depending on claim interpretation and the spec).
- Combination flexibility: dependent claims include optional additional agents across multiple mechanistic classes.
- Biological readouts are optional: marker measurement appears in dependent claims, so a practitioner could use the treatment without running the immunohistochemistry/PCR steps and still fall within the treatment claims unless those steps are required by the asserted dependent claim(s).
What the claims clearly limit (narrow dimensions)
- SEQ ID NO: 28 is mandatory in both independent claims (claims 1 and 15).
- Joint-specific administration is required in the treatment method (claim 1): not systemic-only in the claim text.
- MSC differentiation claims require MSC contact in the induction method (claim 15).
- Procedural linkages are claim-dependent:
- surgery timing (during or after) is in claim 7
- ACI and ACI/MACI linkage is in claims 8-10
- Marker-based characterization is claim-dependent:
- type II collagen/aggrecan (hyaline markers)
- type X collagen (fibrotic marker)
- and the assays (immunohistochemistry, immunocytochemistry, PCR) in dependent claims 11-14
- Specific co-agent lists are used in claim 5 and claim 20. If a competitor’s combination omits listed members, they may avoid those dependent claims, while still potentially infringing claim 1 if SEQ ID NO: 28 polypeptide is used.
Claim-by-Claim Deconstruction: Coverage, Vulnerability, and Design-Around Paths
1. SEQ ID NO: 28 polypeptide into a joint for arthritis or cartilage damage
- Coverage: any arthritis/cartilage-damage regimen using the specific polypeptide entity.
- Main vulnerability for enforceability: if SEQ ID NO: 28 is not clearly enabled for human use across arthritis types, or if the patent’s effective scope is narrower than claim breadth. (This is an enforceability question tied to written description and enablement, not visible in the claim text alone.)
2. Arthritis type limited only in dependent claim
- Osteoarthritis, trauma arthritis, autoimmune arthritis are covered only if an asserted dependent claim is used.
- A defendant could still infringe claim 1 without tying to these arthritis subtypes, since claim 1 already covers “arthritis.”
3. Additional chondrogenic factors
- Depends on what “chondrogenic factors” are in the specification and how broadly claim construction reads them.
- Design-around lever: use anti-inflammatory-only or anti-catabolic agents rather than chondrogenic factors to avoid dependent claim 3.
4. Hyaluronic acid or derivative
- A dependent combination hook.
- Avoidance path: hyaluronic-acid-free regimens.
5. Specific agent set (broad mechanistic list)
Claim 5 includes a closed-ish “selected from the group consisting of” list:
- oral salmon calcitonin
- SD-6010 (iNOS inhibitor)
- vitamin D3 (cholecalciferol)
- collagen hydrolyzate
- FGF18
- BMP7
- rusalatide acetate
- avocado soy unsaponifiables (ASU)
- kartogenin
- a steroid
- an NSAID
Implication: If a regimen uses SEQ ID NO: 28 polypeptide plus an agent not on the list (or not interpreted as “a steroid/NSAID”), it may avoid claim 5 while still hitting claim 1.
Enforcement reality: most defendants will avoid the full combination match to reduce exposure to dependent claims; plaintiffs can still assert claim 1 if the defendant uses the polypeptide regardless of co-agent selection.
6-9. Surgery and regenerative procedure timing/formats
- Claim 6: performs a surgical procedure on the affected joint.
- Claim 7: administer during or after the surgical procedure.
- Claim 8: administer in conjunction with bone marrow stimulation, cartilage replacement, ACI, or MACI.
- Claim 9: administer in conjunction with ACI.
Design-around levers:
- avoid surgery linkage (use non-surgical intra-articular approaches only)
- avoid ACI/MACI context if the defendant is using other cartilage repair paradigms
- timing control can be leveraged against claim 7 (before surgery vs during/after), though claim 7 is dependent.
10. Administered in a matrix or biocompatible scaffold
- Dependent narrowing.
- A developer using a free-form injection might try to avoid scaffold/matrix language, depending on construction. If the competitor’s formulation uses any carrier described as a matrix or scaffold, this hook may still capture them.
11-14. Marker-based before/after expression readouts
- Claim 11: determine expression of hyaline cartilage-specific protein type II collagen or aggrecan pre- and post-treatment
- Claim 12: assays by immunohistochemistry, immunocytochemistry, or PCR
- Claim 13: determine fibrotic cartilage-specific protein type X collagen pre- and post-treatment
- Claim 14: same assay methods
Practical impact:
- These dependent claims are more likely to be asserted in clinical trial protocols, translational studies, or product development dossiers rather than routine clinical use.
- They are also the easiest category for a defendant to avoid procedurally if not required for routine care (unless the patent is asserted against trial data generation).
What the MSC Differentiation Claims Add to the Landscape
15-16. MSC to chondrocyte differentiation using SEQ ID NO: 28
This is a classic second “process” claim family that broadens enforceability beyond direct joint treatment into upstream cell engineering and in vivo cell behavior.
- Claim 15: contact MSCs with SEQ ID NO: 28 polypeptide
- Claim 16: in vivo human subject
17-18. Arthritis/cartilage damage in vivo contexts
- Dependent attachment to arthritis/cartilage damage, and arthritis subtypes.
19-20. Co-factors and agent set
- Dependent co-treatment with:
- hyaluronic acid/derivative
- oral salmon calcitonin
- SD-6010
- vitamin D3
- collagen hydrolyzate
- FGF18
- BMP7
- rusalatide acetate
- ASU
- kartogenin
- a steroid
- an NSAID
Landscape consequence: if a competitor develops an MSC therapy that uses the SEQ ID NO: 28 polypeptide as part of differentiation induction or as an in vivo administered driver, they can be pulled into infringement even if the joint treatment protocol differs.
Critical Patent Landscape Assessment (What Likely Matters for Freedom-to-Operate)
1) The key infringement question is the entity: “polypeptide comprising SEQ ID NO: 28”
The landscape impact of US 10,239,927 is dominated by:
- whether competitors use the same SEQ-defined polypeptide (or a construct that falls within “comprising”)
- whether competitors’ polypeptides are materially distinguishable in sequence identity and claim construction
Business takeaway: market entry risk for cartilage/arthritis biologics rises sharply if the active is sequence-identical or sequence-containing the claimed SEQ ID NO: 28.
2) Combination therapy coverage is fragmented by dependent claims
Even if a product uses the polypeptide, exposure scales with whether it also:
- adds hyaluronic acid (claim 4)
- adds “additional chondrogenic factors” (claim 3 or 19)
- uses any member from claim 5 / 20 listed agent set
This means trial design and label-like regimen documentation matter. A product can reduce infringement footprint by avoiding those dependent combinations, while still potentially facing claim 1 exposure if the polypeptide is used regardless of co-agents.
3) Procedural and formulation hooks are operational mitigations
Claims 6-10 introduce additional layers tied to real-world care pathways:
- surgery context
- ACI/MACI/regenerative procedure context
- scaffold/matrix formulation
A competitor can reduce dependency risk by using non-surgical intra-articular administration and non-scaffold formulations, while still running the risk of claim 1 if the polypeptide is present.
4) Marker-measurement dependent claims influence trial and lab workflows
Claims 11-14 target experimental readouts, which can be highly relevant to:
- internal translational studies
- clinical trial endpoints
- companion diagnostics-like measurement plans
A competitor could avoid marker-determination steps that map exactly to the dependent claims, though independent claim infringement remains possible.
Where the Claims Are Most Likely to Meet Prior Art Pressure
Based on the claim structure alone, novelty is expected to rest on the specific polypeptide (SEQ ID NO: 28) and its use in the arthritis/cartilage and MSC differentiation contexts. Prior art pressure would most plausibly cluster into four buckets:
- Polypeptides that drive chondrogenesis / cartilage repair
- MSC chondrogenic differentiation methods using growth factors and bioactives
- Intra-articular combination regimens (hyaluronic acid, anti-inflammatories, calcitonin, vitamin D3, FGF/BMP signaling modulators, kartogenin-class chondrogenic agents)
- Cartilage repair procedural frameworks (microfracture/bone marrow stimulation, cartilage replacement, ACI/MACI integration)
The dependent claim lists heavily resemble a field-standard combination ecosystem, so the differentiator must be the SEQ ID NO: 28 polypeptide identity and functional role.
Competitive and Investment Implications
Product developers
- Highest-risk design variable: incorporation of the SEQ ID NO: 28 polypeptide in any joint-treatment or MSC differentiation workflow.
- Secondary risk variables: scaffold/formulation, surgery/ACI/MACI alignment, and using co-agents that match claim lists.
R&D program managers
- Structure programs to avoid triggering dependent claims if feasible:
- avoid scaffold claims when using a strictly defined liquid formulation
- avoid surgical/ACI/MACI contexts if the program targets non-procedural intra-articular dosing
- avoid pre/post marker assays that map exactly to the dependent claim language if that is feasible for regulatory evidence planning
- Still assume claim 1 exposure if SEQ ID NO: 28 is in the regimen.
Investors
- Treat US 10,239,927 as a sequence-anchored patent: either you have a clean path (no use of SEQ ID NO: 28 polypeptide), or you likely need a licensing strategy and a deep claim chart.
- Dependent claims can shape settlement posture but rarely eliminate claim 1 exposure if the active is the same polypeptide.
Key Takeaways
- US 10,239,927 claims two method families: joint treatment and MSC differentiation, both driven by a single entity: a polypeptide comprising SEQ ID NO: 28.
- The claim breadth sits in therapeutic context and combination optionality; the narrowness sits in the SEQ-defined polypeptide and in several dependent procedural/formulation/assay hooks.
- The enforceability and competitive risk pivot on whether a competitor’s active molecule contains or functionally reads on SEQ ID NO: 28.
- Dependent claims create regimen-matching exposure: hyaluronic acid, chondrogenic factors, and the listed agent set; plus surgery/ACI/MACI and scaffold/formulation; plus pre/post cartilage marker assays.
FAQs
-
Is SEQ ID NO: 28 the only mandatory requirement across both independent claims?
Yes. Claims 1 and 15 both require a “polypeptide comprising SEQ ID NO: 28.”
-
If a product uses the polypeptide but omits hyaluronic acid, does it still risk infringement?
Yes, because claim 4 (hyaluronic acid) is dependent. Claim 1 can still be asserted if the polypeptide is used for joint treatment.
-
Do the claims require proof of cartilage marker expression to infringe?
No. Marker determination (type II collagen/aggrecan or type X collagen; assay methods) is contained in dependent claims 11-14.
-
Can a competitor reduce risk by avoiding ACI/MACI procedures?
That reduces exposure to dependent claims 8-9, but it does not eliminate potential exposure to claim 1 if the polypeptide is administered to the joint for arthritis/cartilage damage.
-
Does the MSC differentiation claim apply only in vitro?
No. Dependent claim 16 explicitly covers performance in vivo in a human subject.
References
[1] United States Patent 10,239,927 (claim text provided in prompt).
